No Data
FDA to Cut Animal Testing in Cancer Drug Development
Merck Announces FDA Breakthrough Therapy Designation For Calderasib, An Investigational Oral Specific KRAS G12C Inhibitor, In Combination With Keytruda
Express News | FDA Grants Breakthrough Therapy Designation for Calderasib (Mk-1084), an Investigational Kras G12C Inhibitor, for Certain Patients With Newly Diagnosed Metastatic Kras G12C-Mutant Non-Small Cell Lung Cancer (Nsclc)
Merck Shareholders Back Board, Pay and Auditor Ratification
Regeneron, Gilead Therapies Eyed as Potential Ebola Treatments by WHO
Express News | Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care

102711703 : https://x.com/cnevpost/status/2057799305684255154?s=46&t=Vexan2WfHJ5soHfuls5bXw
creative Buffalo_w1v : why moomoo never cover the news of futu stock crash?
creative Buffalo_w1v : com/markets/sto...
Yoke Kee Sim716 : ok